Biotech Market Dynamics
A significant downturn in the biotech sector saw stocks plummet 64%, with many companies trading below their cash reserves, indicating a market perception that their R&D was worthless. Despite this bleak outlook, early commercial companies with substantial revenues but no profits began to emerge as undervalued opportunities. As M&A activity picks up, the landscape for investment in biotech is evolving, revealing potential where the market had previously overlooked value.In this clip
From this podcast
Capital Allocators – Inside the Institutional Investment Industry
[REPLAY] Andy Acker - Empty Rooms: Investing in Biotech at Janus Henderson (Capital Allocators, EP.274)
Related Questions
How do you evaluate startups effectively in the episode Biotech Revolution with Software Engineering Daily and the clip Evaluating Biotech Investments?
I have a question about the episode Drugging the Undruggable with Greg Verdine and the clip Startup vs. Industry: How does R\&D in big enterprises compare to startups?